CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Outcome of patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention during on- versus off-hours (a Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction [HORIZONS-AMI] trial substudy) 2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention and the 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infa Impact of treatment delay on mortality in ST-segment elevation myocardial infarction (STEMI) patients presenting with and without haemodynamic instability: results from the German prospective, multicentre FITT-STEMI trial National assessment of early β-blocker therapy in patients with acute myocardial infarction in China, 2001-2011: The China Patient-centered Evaluative Assessment of Cardiac Events (PEACE)-Retrospective AMI Study Trends and Impact of Door-to-Balloon Time on Clinical Outcomes in Patients Aged <75, 75 to 84, and ≥85 Years With ST-Elevation Myocardial Infarction Fate of post-procedural malapposition of everolimus-eluting polymeric bioresorbable scaffold and everolimus-eluting cobalt chromium metallic stent in human coronary arteries: sequential assessment with optical coherence tomography in ABSORB Japan trial Early invasive versus non-invasive treatment in patients with non-ST-elevation acute coronary syndrome (FRISC-II): 15 year follow-up of a prospective, randomised, multicentre study Clinical value of post-percutaneous coronary intervention fractional flow reserve value: A systematic review and meta-analysis Diagnostic performance of noninvasive fractional flow reserve derived from coronary computed tomography angiography in suspected coronary artery disease: the NXT trial (Analysis of Coronary Blood Flow Using CT Angiography: Next Steps) Coronary Artery Plaque Characteristics Associated With Adverse Outcomes in the SCOT-HEART Study
|<<... 15 16 17 18 19 20 21 ...>>|

Original Research

JOURNAL：ACC Article Link

房颤合并慢性肾病的抗凝策略

CBSMD

Pre-reading

房颤(Atrial fibrillation， AF)和慢性肾脏疾病( chronic kidney disease ，CKD)的多种致病因素常存在共通性，如高血压、糖尿病和冠状动脉疾病。当不合并CKD时，对房颤患者开展抗凝治疗是毋庸置疑的，但此做法不适用于房颤合并晚期CKD的患者群（advanced CKD）。随着CKD患者肾功能的下降，缺血性卒中和出血的危险逐渐增加，使抗凝治疗趋向复杂。现存随机对照试验尚不能得出可明确辅助临床决策的指南性意见，而观察性研究的结果相互矛盾。在最新JACC综述“Anticoagulation in Concomitant Chronic Kidney Disease and Atrial Fibrillation: JACC Review Topic of the Week”中,作者概述了相关病理生理学机制,总结CKD合并AF的抗凝策略及研究进展， 并就如何在这些患者中使用口服抗凝给出建议。

该文核心要点可参阅CBSMD文献导读“Anticoagulation in Concomitant CKD and AF”。



>CBS CBS 2019

> CBS 2019

> CBS 2019 注册

> CBS 2019 会议日程

> CBS 2019 学术征集

> CBS 2019 热点

 CBSMD

> CBSMD 网站注册

> 教育中心

> 荐读文献

> Top 10 阅读文献

> 文献导读
CBS 2019 CBS 2019 主席团 教育中心 科研动态
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top